Clinical trials: Atorvastatin, completed
Statin Myopathy
Evaluation of Patients With Statin Myopathy Using an N of 1 Trial Design
This study consists of a series of prospective, randomized placebo-controlled n of 1 trials to objectively evaluate the reproducibility of subjective and objective symptoms among patients with a history of statin-related myopathy.
- Trial name
- NCT01259791
- Testing
- Individual-specific statin causing myopathy
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Type 1 Diabetes
Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)
The goal of this application is to evaluate the safety and efficacy of atorvastatin as a potential treatment to preserve beta cell function in children and young adults with newly diagnosed type 1 diabetes (T1DM).
- Trial name
- TIDM (NCT00529191)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Philadelphia
Coronary Artery Disease, HMG-CoA Reductase Inhibitor Toxicity
Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients
The present study constitutes a study examining the effect of atorvastatin on vascular function in high cardiovascular risk patients.
- Conditions
- Coronary Artery Disease, HMG-CoA Reductase Inhibitor Toxicity, Atherosclerosis, Oxidative Stress
- Trial name
- NCT01013103
- Testing
- Atorvastatin, high vs low dose
- Where
- Greece
- Volunteers
- 72 people
- Sponsor
- Hippocration General Hospital
Type 2 Diabetes Mellitus
Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)
The aim of this study is to examine the effect of intensive cholesterol lowering therapy and tight blood pressure (BP) regulation on endothelial function (inner cell layer of vessels that determines dilatation) in type 2 diabetic…
- Trial name
- NCT00124397
- Testing
- Atorvastatin
- Where
- Denmark
- Volunteers
- 186 people
- Sponsor
- University of Southern Denmark
Dyslipidemia in Patients With Diabetes Mellitus
The HDL Particle Protection Study
Atorvastatin is a statin that significantly decreases LDL level. At 10 mg/day, atorvastatin increases HDL level by 4-5%. At 80 mg/day, atorvastatin does not increase HDL level.
- Trial name
- HDL PROTECT (NCT02125682)
- Testing
- atovastatin 10 mg/day, Atorvastatin 80 mg/day
- Where
- Lebanon
- Volunteers
- 16 people
- Sponsor
- Hotel Dieu de France Hospital
Statin, Coronary Plaque
Extended Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome
The objective of this study is to verify the relationship between coronary plaque regression and cardiovascular prevention in long term follow up of the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome…
- Conditions
- Statin, Coronary Plaque, Acute Coronary Syndrome, Intravascular Ultrasound
- Trial name
- Ex JAPAN-ACS (NCT01223586)
- Where
- 2 sites in Japan
- Volunteers
- 238 people
- Sponsor
- Kyoto University
COPD
The Effects of Atorvastatin Treatment in COPD Patients
Rationale: Retrospective studies suggest that statins improve outcomes in COPD patients possibly as a result of an anti-inflammatory effect.
- Trial name
- NCT01748279
- Testing
- Atorvastatin, Formoterol, Lactose tablet
- Where
- Poland
- Volunteers
- 18 people
- Sponsor
- Medical University of Bialystok
Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Mellitus
Statins in Patients With Type 2 Diabetes Mellitus and Previous History of Acute Coronary Syndrome
The purpose of this study was to compare the efficacy and safety of high dose atorvastatin (40 mg) versus high dose rosuvastatin (20 mg) in Egyptian type II diabetic patients with previous acute coronary syndrome history.
- Trial name
- NCT05306990
- Testing
- Atorvastatin 40 Mg Oral Tablet, Rosuvastatin 20 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 108 people
- Sponsor
- Helwan University
Diabetes Mellitus, Metabolic Syndrome X
Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells
Thirty-six subjects with hyperlipidemia and metabolic syndrome and/or diabetes were randomized in a double-blind manner to either pravastatin 80 mg or atorvastatin 10 mg daily.
- Conditions
- Diabetes Mellitus, Metabolic Syndrome X, Hypercholesterolemia
- Trial name
- STOPCAP (NCT00166036)
- Testing
- Atorvastatin, Pravastatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Emory University
Hypertension, Hyperlipidemia
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels
The purpose of the study is to measure the effect of the amlodipine/atorvastatin combination pill in reducing both elevated blood pressure and cholesterol levels to levels suggested by guidelines
- Trial name
- GEMINI-AALA (NCT00143234)
- Testing
- Amlodipine/atorvastatin single pill
- Where
- 118 sites in Argentina, Australia and 25 more
- Volunteers
- 1,825 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Endocrine System Diseases
Diabetic Treatment Adherence
The goal of this clinical research study is to test an investigational type of packaging for diabetes drugs called "unit-dose packaging." Researchers want to learn if unit-dose packaging can help patients with Type II diabetes to…
- Trial name
- NCT01318564
- Testing
- Metformin, Questionnaires
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Rheumatoid Arthritis
Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550
All patients will be in instructed to eat a therapeutic lifestyle diet and will receive CP-690,550 throughout the 12 weeks of this study.
- Trial name
- NCT01059864
- Testing
- CP-690,550, Atorvastatin
- Where
- 15 sites in United States, South Korea
- Volunteers
- 111 people
- Sponsor
- Pfizer
Hypercholesterolemia, Dyslipidemia
Atorvastatin Study in Cardiovascular Disease Risk
Treatment of hypercholesterolemia is based on the guidelines of ESC-EAS 2011 (European Heart Journal (2011) 32, 1769-1818, ESC / EAS Guidelines for the management of dyslipidaemias) These calculate the 10 year risk based on SCORE…
- Trial name
- ANTLER (NCT02392416)
- Where
- 2 sites in Greece
- Volunteers
- 900 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Hypercholesterolemia
A Study in People With High Cholesterol
The purposes of this study are to determine: The safety of the study medication and any side effects that might be associated with it Whether the study medication can help patients with high levels of "bad" cholesterol…
- Trial name
- NCT00133380
- Testing
- PPAR alpha, atorvastatin
- Where
- 28 sites in United States
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Relapsing-remitting Multiple Sclerosis
Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b
The "SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study" is the follow up study of the "SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS)" (see…
- Trial name
- NCT01111656
- Testing
- Interferon beta-1b group, Interferon beta-1b/Atorvastatin group
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Hypercholesterolemia, Atherosclerosis
Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)
To compare the efficacy of ezetimibe 10 mg added daily to ongoing treatment with atorvastatin 10 mg daily versus ezetimibe placebo added daily to ongoing treatment with atorvastatin 10 mg daily in reducing the concentration of…
- Trial name
- NCT00651404
- Testing
- Ezetimibe
- Volunteers
- 137 people
- Sponsor
- Organon and Co
Hypertension, Hyperlipidemia
Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.
To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.
- Trial name
- JEWEL II (NCT00174304)
- Testing
- Amlodipine/atorvastatin single pill
- Where
- 102 sites in Austria, Belgium and 9 more
- Volunteers
- 1,120 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia
The purpose of this study is to determine the efficacy of lapaquistat acetate, once daily (QD), coadministered with a statin to lower lipid levels in Subjects with Hypercholesterolemia.
- Trial name
- NCT00864643
- Testing
- Lapaquistat acetate and atorvastatin, Atorvastatin
- Volunteers
- 172 people
- Sponsor
- Takeda
Osteoporosis, Hypercholesterolemia
Effect of Atorvastatin on Bone-vascular Axis
Background: Circulating osteoprogenitors and RANKL expression in immune cells have been implicated in the pathogenesis of osteoporosis and vascular calcification.
- Trial name
- NCT02342015
- Testing
- Atorvastatin
- Volunteers
- 20 people
- Sponsor
- University of Padova
Coronary Artery Disease, Menopause
Serum Concentration of Endogenous Estrogens and Sirtuin-1 After Administration of Atorvastatin and Quercetin:
Chronic coronary syndrome (CCS) is the leading cause of death in women in the most developed regions of Brazil. The primary etiopathogenic mechanism is the process of atherosclerosis.
- Trial name
- NCT05877235
- Testing
- Quercetin
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- InCor Heart Institute